XML 41 R23.htm IDEA: XBRL DOCUMENT
v3.20.4

Other assets impairments, restructuring and other items | 12 Months Ended
--- | ---
Dec. 31, 2020
Other assets impairments, restructuring and other items | NOTE 15—Other assets impairments, restructuring and other items:
|  | Year ended December 31, |
|  | 2020 |  |  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
Impairment of long-lived tangible assets (1) |  | $ | 416 |  |  | $ | 139 |  |  | $ | 500 |
Contingent consideration (see note 2) |  |  | (81 | ) |  |  | 59 |  |  |  | 57 |
Restructuring |  |  | 120 |  |  |  | 199 |  |  |  | 488 |
Other |  |  | 24 |  |  |  | 26 |  |  |  | (58 | )
Total |  | $ | 479 |  |  | $ | 423 |  |  | $ | 987 |
(1) | Including impairments related to exit and disposal activities.
Following Teva’s two-year restructuring plan, described below, and its ongoing plant rationalization efforts, the Company may change its current plans with respect to any given asset and/or the assumptions underlying such plans. Consequently, additional impairments may be recorded in the future. Impairments Impairments of tangible assets for the years ended December 31, 2020, 2019 and 2018 were $416 million , $139 million and $500 million, respectively. The impairment for the year ended December 31, 2020 was mainly related to the sale of certain assets from Teva’s business venture in Japan , which was completed on February 1, 2021, as well as plant rationalization. See note 2. Contingent consideration In 2020, Teva recorded an income of $81 million for contingent consideration, compared to an expense of $59 million and $57 million in 2019 and 2018 respectively. The income in 2020 was mainly related to a change in the future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid ® ), which was part of the Actavis Generics acquisition, partially offset by the change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. The expense in 2019 was mainly related to a change in the estimated future royalty payments from Eagle in connection with bendamustine sales and an increase in the expected future royalty payments to Eagle due to the orphan drug status granted to BENDEKA ® , offset by the change in future royalty payments in connection with lenalidomide (generic equivalent of Revlimid ® ), which was part of the Actavis Generics acquisition. Restructuring In 2020, Teva recorded $120 million of restructuring expenses, compared to $199 million in 2019 and $488 million in 2018. The expenses in 2020 were primarily related to residual expenses of the restructuring plan announced in 2017 and other network consolidation impacts. In December 2017, Teva announced a comprehensive two-year restructuring plan intended to reduce its cost base by $3 billion, unify and simplify its organization and improve business performance, profitability, cash flow generation and productivity. This plan achieved its goals, including a total cost base reduction of $3 billion by the end of 2019. Teva is continuing to evaluate opportunities to further optimize its manufacturing and supply network to achieve additional operational efficiencies. The following tables provide the components of costs associated with Teva’s restructuring plan, including other costs associated with Teva’s restructuring plan and recorded under different items:
|  | Year ended December 31, |
|  | 2020 |  |  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
Restructuring |  |  |  |  |  |  |  |  |  |  |  |
Employee termination |  | $ | 71 |  |  | $ | 159 |  |  | $ | 410 |
Other |  |  | 49 |  |  |  | 40 |  |  |  | 78 |
Total |  | $ | 120 |  |  | $ | 199 |  |  | $ | 488 |
The following table provides the components of and changes in the Company’s restructuring accruals:
|  | Employee termination costs |  |  | Other |  |  | Total |
|  | (U.S. $ in millions ) |
Balance as of January 1, 2019 |  | $ | (204 | ) |  | $ | (29 | ) |  | $ | (233 | )
Provision |  |  | (159 | ) |  |  | (40 | ) |  |  | (199 | )
Utilization and other* |  |  | 155 |  |  |  | 62 |  |  |  | 217 |
Balance as of December 31, 2019 |  | $ | (208 | ) |  | $ | (7 | ) |  | $ | (215 | )
Provision |  |  | (71 | ) |  |  | (49 | ) |  |  | (120 | )
Utilization and other * |  |  | 164 |  |  |  | 49 |  |  |  | 213 |
Balance as of December 31, 2020 |  | $ | (115 | ) |  | $ | (7 | ) |  | $ | (122 | )
* | Includes adjustments for foreign currency translation.
Significant regulatory and other events In July 2018, the FDA completed an inspection of Teva’s manufacturing plant in Davie, Florida in the United States, and issued a Form FDA-483 to the site. In October 2018, the FDA notified Teva that the inspection of the site is classified as “official action indicated” (OAI). On February 5, 2019, Teva received a warning letter from the FDA that contained four additional enumerated concerns related to production, quality control and investigations at this site. Teva has been working diligently to address the FDA’s concerns in a manner consistent with current good manufacturing practice (cGMP) requirements as quickly and as thoroughly as possible. An FDA follow up inspection occurred in January 2020, resulting in some follow up findings and Teva received a letter from the FDA dated April 24, 2020 notifying it that the site continues to be classified as OAI. If Teva is unable to remediate the findings to the FDA’s satisfaction, Teva may face additional consequences. These would potentially include delays in FDA approval for future products from the site, financial implications due to loss of revenues, impairments, inventory write-offs, customer penalties, idle capacity charges, costs of additional remediation and possible FDA enforcement action. Teva expects to generate approximately $190 million in revenues from this site in 2021, assuming remediation or enforcement does not cause any unscheduled slowdown or stoppage at the facility, however, delays in FDA approvals of future products from the site may occur. In July 2018, Teva announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of a previously unknown nitrosamine impurity called NDMA found in valsartan API supplied by Zhejiang Huahai Pharmaceuticals Co. Ltd. (“Huahai”). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva’s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue. In addition, multiple lawsuits have been filed in connection with this matter, which may lead to additional customer penalties, impairments and litigation costs. In the second quarter of 2020, Teva’s operations in its manufacturing facilities in Goa, India were temporarily suspended due to a water supply issue. During the second half of 2020, Teva has completed partial remediation of this issue and has restarted limited supply from its Goa facilities. The impact to Teva’s financial results for the twelve months ended December 31, 2020 was immaterial, however, if the full remediation takes longer than expected there may be further loss of sales, customer penalties or impairments to related assets.

X
- Definition Other Expenses [Text Block] + References No definition available. + Details
Name: | teva_OtherExpensesTextBlock
Namespace Prefix: | teva_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration